PFM Health Sciences’s DexCom DXCM Stock Holding History

PFM Health Sciences’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-348,800	Closed	-$31.3M	–	88
2021 Q1	$31.3M	Buy	+348,800	New	+$32.7M	0.96%	41

Other funds holding DXCM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

PFM Health Sciences's DXCM Position: Q2 2026 in Review

PFM Health Sciences sold out of DexCom (DXCM) in Q2 2026, closing a stake of 149,734 shares — an estimated $9.4M sold.

PFM Health Sciences first reported a position in DXCM in Q4 2015 and held it in 19 quarters. The position peaked at $63.9M in Q3 2019. 973 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

PFM Health Sciences reported no remaining DexCom position as of Q2 2026 after selling out during the quarter.
PFM Health Sciences sold 149,734 DexCom shares in Q2 2026, an estimated $9.4M.
PFM Health Sciences first reported a position in DexCom in Q4 2015 and held it in 19 quarters.
PFM Health Sciences's DexCom position peaked at $63.9M in Q3 2019.
973 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on PFM Health Sciences's 13F filing for Q2 2026, filed 14 Aug 2026.